Introgen falls on Advexin data

Introgen fell $0.75 (27%) to $2.05 on Wednesday after reporting additional data from the Phase III T301 trial of Advexin to treat recurrent squamous cell carcinoma of the head and neck (SCCHN). Data from the open-label, U.S. study showed that in the intent-to-treat population of 123 patients, the adenovirus p53 tumor suppressor gene therapy failed to significantly improve overall survival, the primary endpoint, vs. methotrexate alone (6.1 vs. 4.4 months, p=0.236). Introgen said Advexin patients who had tumor responses had a significant increase in survival vs. Advexin non-responders (7.6 vs. 2.9 months, p=0.0002). Data will be presented on Thursday at the American Society for Gene Therapy meeting in Boston. ...